Skip to main content
Top
Published in: International Journal of Hematology 2/2018

01-08-2018 | Original Article

Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center

Authors: Xuemei Wu, Suli Wang, Xingyu Lu, Wenyi Shen, Chun Qiao, Yujie Wu, Ruinan Lu, Shuai Wang, Jianfu Zhang, Ming Hong, Yu Zhu, Jianyong Li, Guangsheng He

Published in: International Journal of Hematology | Issue 2/2018

Login to get access

Abstract

To assess response to cyclosporine A, and/or corticosteroids, and possible factors influencing the response in adult patients with acquired pure red cell aplasia (PRCA). Clinical data from 42 cases were retrospectively analyzed. These patients received cyclosporine A (CsA), and/or corticosteroids (CS), or other immunosuppressive agents on becoming refractory and relapse. Thirty-nine patients were evaluated. Remission induction therapy included CsA (n = 16), CS (n = 13), CsA in combination with CS (n = 6), or other immunosuppressive agents (n = 4). Initial response rates were 75.0, 46.2, 66.7 and 75.0%, respectively (P = 0.456). Cumulative response rates in patients who received CsA, CS, CsA in combination with CS, or other immunosuppressive agents were 69.6% (16/23), 50.0% (7/14), 71.4% (5/7), 42.9% (6/14), respectively (P = 0.376). Cumulative rates of CR were 26.1% (6/23), 28.6% (4/14), 57.1% (4/7), 14.3% (2/14), respectively (P = 0.284). In 27 refractory and relapsed PRCA patients, 11 of 17 patients (64.7%) achieved remission by CsA and/or CS regimen, while three of ten patients (30.0%) responded to other immunosuppressive agents (P = 0.120). CsA and/or CS were effective in treating PRCA. For patients with relapse or refractory PRCA, there were no satisfactory treatments if CsA and/or CS failed or were not administered.
Literature
1.
go back to reference Dessypris EN, Lipton JM. Red cell aplasia. In: Wintrobe’s clinical hematology. 11th ed. Philadelphia: Lippincott Williams &Wilkins; 2004. p. 1421–1427. Dessypris EN, Lipton JM. Red cell aplasia. In: Wintrobe’s clinical hematology. 11th ed. Philadelphia: Lippincott Williams &Wilkins; 2004. p. 1421–1427.
2.
go back to reference Goldman L, Schafer AI. Aplastic anemia and related bone marrow failure states. In: Bagby GC, editor. Goldman’s cecil medicine. 24th ed. New York: Elsevier; 2011. p. 1083–90. Goldman L, Schafer AI. Aplastic anemia and related bone marrow failure states. In: Bagby GC, editor. Goldman’s cecil medicine. 24th ed. New York: Elsevier; 2011. p. 1083–90.
3.
5.
go back to reference Marmont AM. Therapy of pure red cell aplasia. Semin Hematol. 1991;28:285–97.PubMed Marmont AM. Therapy of pure red cell aplasia. Semin Hematol. 1991;28:285–97.PubMed
6.
go back to reference Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87:3000–6.PubMed Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87:3000–6.PubMed
7.
go back to reference Mamiya S, Itoh T, Miura AB. Acquired pure red cell aplasia in Japan. Eur J Haematol. 1997;59:199–205.CrossRefPubMed Mamiya S, Itoh T, Miura AB. Acquired pure red cell aplasia in Japan. Eur J Haematol. 1997;59:199–205.CrossRefPubMed
8.
go back to reference Zecca M, Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed Zecca M, Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMed
9.
go back to reference Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocyticleukemia. Blood. 2002;99:1092–4.CrossRefPubMed Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocyticleukemia. Blood. 2002;99:1092–4.CrossRefPubMed
10.
go back to reference Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003;123:278–81.CrossRefPubMed Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003;123:278–81.CrossRefPubMed
12.
go back to reference Sawada K, Hirokawa M, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007;92:1021–8.CrossRefPubMed Sawada K, Hirokawa M, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007;92:1021–8.CrossRefPubMed
13.
go back to reference Hirokawa M, Sawada K, Nakao S, Fujishima N, Nakao S, Urabe A, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008;93:27–33.CrossRefPubMed Hirokawa M, Sawada K, Nakao S, Fujishima N, Nakao S, Urabe A, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008;93:27–33.CrossRefPubMed
14.
go back to reference Dessypris EN. Pure red cell aplasia. Baltimore: Johns Hopkins University Press; 1988. Dessypris EN. Pure red cell aplasia. Baltimore: Johns Hopkins University Press; 1988.
15.
go back to reference Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11):4831–8.PubMed Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11):4831–8.PubMed
16.
go back to reference Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93:518–23.CrossRefPubMed Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93:518–23.CrossRefPubMed
17.
go back to reference Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M, et al. Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009;82:308–14.CrossRefPubMed Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M, et al. Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009;82:308–14.CrossRefPubMed
18.
go back to reference Kwong YL, Au WY, Leung AY, Tse EW. T-cell large granu1ar lymphocyte leukemia: an Asian perspective. Ann Hematol. 2010;89(4):331–9.CrossRefPubMed Kwong YL, Au WY, Leung AY, Tse EW. T-cell large granu1ar lymphocyte leukemia: an Asian perspective. Ann Hematol. 2010;89(4):331–9.CrossRefPubMed
19.
go back to reference Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20:245–66.CrossRefPubMed Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20:245–66.CrossRefPubMed
20.
21.
go back to reference Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, Zhou JF, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol. 2013;6:82.CrossRefPubMedPubMedCentral Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, Zhou JF, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol. 2013;6:82.CrossRefPubMedPubMedCentral
22.
go back to reference Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Uezono S, et al. Clinical characteristics and outcomes of 11 patients with pure red cell aplasia at a single institution over a 13-year period. Intern Med. 2013;52:2025–30.CrossRefPubMed Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Uezono S, et al. Clinical characteristics and outcomes of 11 patients with pure red cell aplasia at a single institution over a 13-year period. Intern Med. 2013;52:2025–30.CrossRefPubMed
23.
go back to reference Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93:1555–9.CrossRefPubMed Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93:1555–9.CrossRefPubMed
24.
go back to reference Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015;169:879–86.CrossRefPubMed Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015;169:879–86.CrossRefPubMed
Metadata
Title
Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center
Authors
Xuemei Wu
Suli Wang
Xingyu Lu
Wenyi Shen
Chun Qiao
Yujie Wu
Ruinan Lu
Shuai Wang
Jianfu Zhang
Ming Hong
Yu Zhu
Jianyong Li
Guangsheng He
Publication date
01-08-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 2/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2446-y

Other articles of this Issue 2/2018

International Journal of Hematology 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine